ClinicalTrials.gg
CompletedNCT05898711Updated Nov 13, 2026

Kerecis Case Registry for SurgiBind : Soft Tissue Reinforcement

An observational study in Surgery-Complications, sponsored by Kerecis Ltd.. Completed at 4 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Kerecis Ltd. (part of Coloplast A/S) · Observational

How we know

Updated Nov 13, 2026Now CompletedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
75
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Registry Objectives The overall objective of the registry is to collect quality and safety data to assess the long-term outcomes of Kerecis Omega3 SurgiBind in surgical procedures to reinforce soft tissue and prevent surgical complications. The ultimate goal of the registry is to enhance the quality of care, patient outcomes and establish a resource to facilitate the use of fish skin in preventing surgical wound dehiscence and surgical site infection.

Read the detailed description

This Registry is a non-experiment non-interventional case registry to collect quality and safety data on patients that have been treat with the Kerecis product SurgiBind as their regular operative plan from their health care provider.

Primary Objective To collect and quantify patient safety and quality outcomes on a commercially available FDA cleared product Kerecis Omega3 SurgiBind utilized in surgical treatment to reinforce soft tissue and preventing surgical complications (dehiscence and infection).

Secondary Objective To assess the applicable complications post-surgery following the use of fish skin regarding time to heal, time to physical therapy, length of stay, etc.

Registry Procedures Specific Training Prior to patient enrollment, the Sponsor will initiate in person or virtual site visit with participating sites to provide training to the physicians and their staff about the protocol, registry procedures and data entry. The Sponsor will implement a number of strategies to ensure the quality, consistency and interpretability of data recorded. Training, education and ongoing liaison with participating sites will be provided to support high quality data collection.

Recruitment of participants Patients contacting the participating site to schedule the appointment for consultation about their upcoming surgery will be informed about the registry and will be given the option to participate. When the patient comes to the clinic for their visit, information regarding registry participation will be provided by a qualified research staff member. This oral information will be provided while the person is in a private room. Patients can also be recruited through recommendation from their doctors and health care providers.

Data Collection When a subject enrolls in the registry, a unique subject identification number will be assigned. After registry enrollment, data will be collected by the registry physician or trained site personnel either during the routine clinical visit or by telephone contact.

Registry Duration Patients will remain active in the registry for a period of 12 months, no additional information will be collected after that time. Registry enrollment will be for a period of at least 2 years. Registry analysis will be completed in 3 years.

Data Management and Quality Plan Data De-identification Patients enroll in the registry will be assigned a unique subject identification number. This number will consist of ten characters for the registry protocol number, three digits for a site number and four digits for a sequentially assigned subject number (i.e., 0001, 0002, 0003, etc.).

Data Confidentiality, Storage, and Retention All clinicians and related medical staff involved in looking after patients during the study are bound by medical confidentiality and are obliged to comply with data protection follow all Health Information Portability and Accountability Act of 1996 (HIPAA) and Protected Health Information (PHI). Data security is compliance with applicable federal and state laws, rule and regulations, including HIPAA regulation. Research results relating to this study are intended for use in an anonymous form in scientific publications. Personnel who process, generate report or otherwise have contact with PHI must uphold the patient's rights to confidentiality and will be trained in HIPAA privacy and security. If individuals authorized to view records are not bound by medical confidentiality as mentioned above, personal data that come to their attention during checks are confidential under the Data Protection Act.

Data will be collected in a form of case report form (CRF) and entered into secure, web-based portal databases. All users of the databases will need to log in to the databases through a pre-configured username and password controlled by administrator of the system. The databases are housed and managed in an International Organization for Standardization (ISO) 27001 certified environment. Only authorized users and site administrator can see site-wide data. Surgeon Users can only see their procedure. The registry will contain a built-in exporting function to enable data extraction by participating sites to help clinicians review their practice and improve the services. The paper formed CRF will be stored in a locked file cabinet at the participating sites and will be shredded after 7 years post completion of the registry.

Data Quality The registry will implement several strategies to maintain data quality and consistency such as routine cleaning, quality check and periodic feedback. Training, education and ongoing liaison with participating sites will be provided to supporting high quality data collection.

Data Sharing Data can only be shared between participating sites upon request that will be reviewed and approved by the Registry staff. The shared data is only for the purpose of clinical practice improvements, training models and benefiting the patient wellbeing. The registry staff will also provide participating sites with site reports on a regular basis.

02

Conditions studied

  • Surgery-Complications
03

In context

Lead sponsor

Kerecis Ltd. is the lead sponsor of 14 studies on the registry; 3 are open to participants now.

First submitted before Kerecis Ltd. became part of Coloplast A/S.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients over the age of 18 that are scheduled for surgery and part of their surgical plan is to be treated with Kerecis SurgiBind product for soft tissue reinforcement.

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria

    1. Age 18 and older
    2. Undergoing surgical procedure requiring soft tissue reinforcement with Kerecis Omega3 SurgiBind

      For example:

      1. Plastic reconstructive surgery
      2. Orthopedic surgery
      3. Cardiothoracic surgery
      4. Vascular Surgery
      5. General Surgery

      Exclusion Criteria:

    <!-- -->

    1. Participants who request not to be in the registry
    2. of less than 1 year
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
75 participants (actual)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • All patients

    All patients who meet inclusion/exclusion criteria

    Device: Fish skin graft

Interventions

  • DeviceFish skin graft

    Kerecis Fish Skin Graft - SurgiBind

06

What researchers measure

Primary outcomes

  1. Number of surgical complication: dehiscence, infection

    quantify the number of patients who experience postoperative wound complications including dehiscence and infection. Patients undergoing surgical procedures and experience wound complications are captured. Wound dehiscence will be categorized as superficial or deep. Infection (if appears) will be identified and recorded. Wounds are considered infected if the wound margins are erythematous and have one or combined of the following: active purulence or necrosis of underlying soft tissues.

    Time frame: 12 months

Secondary outcomes

  1. Time to healing:

    Time to healing: wounds are considered healed when the incision is completely epithelialized with no surrounding erythema

    Time frame: 12 months

  2. Time to physical therapy initiation

    Time it takes for patient to begin physical therapy after the surgical procedure

    Time frame: 12 months

  3. Duration of physical therapy

    How long patient required physical therapy after surgery

    Time frame: 12 months

07

Study locations

4 sites
  • Northern Illinois Foot and Ankle Specialists
    Crystal Lake, Illinois 60014, United States
  • Mount Sinai
    New York, New York 10019, United States
  • Cone Health OrthoCare Greensboro
    Greensboro, North Carolina 27401, United States
  • Kerecis
    Arlington, Virginia 22201, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2022 to primary completion in Oct 2024, 31 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Jan 2022 → Mar 2022, primary completion Jun 2025 → Oct 2024 and completion Jan 2026 → Jan 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2023
First posted
Jun 12, 2023
StartActual
Mar 25, 2022was Jan 2022
Primary completionActual
Oct 29, 2024was Jun 2025
CompletionActual
Jan 3, 2025was Jan 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 13, 2026
Sites
3 sites added
Show 3 added (3 United States)
  • Northern Illinois Foot and Ankle Specialists · Crystal Lake, United States
  • Mount Sinai · New York, United States
  • Cone Health OrthoCare Greensboro · Greensboro, United States
Nov 13, 2026
Start date
Jan 27, 2022→Mar 25, 2022
Nov 13, 2026
Primary completion
Jun 27, 2025→Oct 29, 2024 (actual)
Nov 13, 2026
Study completion
Jan 27, 2026→Jan 3, 2025 (actual)
Nov 13, 2026
Enrollment
200 (estimated)→75 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Active, not recruiting→Completed
    3 sites added
    Show 3 added (3 United States)
    • Northern Illinois Foot and Ankle Specialists · Crystal Lake, United States
    • Mount Sinai · New York, United States
    • Cone Health OrthoCare Greensboro · Greensboro, United States
    Start date Jan 27, 2022→Mar 25, 2022
    Primary completion Jun 27, 2025→Oct 29, 2024 (now actual)
    Study completion Jan 27, 2026→Jan 3, 2025 (now actual)
    Enrollment 200 (estimated)→75 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05898711
Lead sponsor
Kerecis Ltd.
Responsible party
Sponsor
First posted
Jun 12, 2023
Start date
Mar 25, 2022
Primary completion
Oct 29, 2024
Completion
Jan 3, 2025
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion